Biogen's most recent trend suggests a bullish bias. One trading opportunity on Biogen is a Bull Put Spread using a strike $237.50 short put and a strike $232.50 long put offers a potential 44.93% return on risk over the next 6 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $237.50 by expiration. The full premium credit of $1.55 would be kept by the premium seller. The risk of $3.45 would be incurred if the stock dropped below the $232.50 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Biogen is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Biogen is bullish.
The RSI indicator is at 61.27 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Biogen
An AI Firm Wants to Predict Costly Pharma Flops
Thu, 11 Apr 2019 04:00:00 +0000
A German artificial-intelligence firm had come to a different conclusion. Innoplexus AG, a closely held company based in the outskirts of Frankfurt, uses an algorithm to analyze pharma companies’ drug pipelines that it says takes more data and context into account than any other tool. Its assessment of Biogen’s aducanumab gave about a 70 percent to 90 percent chance that the trial would miss its goal.
Raymond James: Biogen's Business Appears Fragile, Faces Many Headwinds
Wed, 10 Apr 2019 13:59:21 +0000
Last month, Biogen Inc (NASDAQ: BIIB ) halted Phase 3 trials for aducanumab in March based on results of a futility analysis conducted by an independent data monitoring committee. While the remaining …
Biogen (BIIB) Dips More Than Broader Markets: What You Should Know
Tue, 09 Apr 2019 21:45:09 +0000
Biogen (BIIB) closed the most recent trading day at $237.58, moving -0.9% from the previous trading session.
6 Predictable Guru Stocks
Tue, 09 Apr 2019 21:01:39 +0000
According to the GuruFocus All-in-One Screener, the following companies have high business predictability ratings and a wide margin of safety. The company has a three out of five-star business predictability rank and, according to the discounted cash flow calculator, a 75.47% margin of safety at $25 per share. Warning! GuruFocus has detected 5 Warning Signs with BHC.
See what the IHS Markit Score report has to say about Biogen Inc.
Tue, 09 Apr 2019 14:50:15 +0000
Biogen Inc NASDAQ/NGS:BIIBView full report here! Summary * ETFs holding this stock are seeing positive inflows * Bearish sentiment is low * Economic output in this company's sector is expanding Bearish sentimentShort interest | PositiveShort interest is extremely low for BIIB with fewer than 1% of shares on loan. This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Money flowETF/Index ownership | PositiveETF activity is positive. Over the last month, growth of ETFs holding BIIB is favorable, with net inflows of $28.35 billion. This is among the highest net inflows seen over the last one-year and the rate of additional inflows appears to be increasing. Economic sentimentPMI by IHS Markit | PositiveAccording to the latest IHS Markit Purchasing Managers' Index (PMI) data, output in the Healthcare sector is rising. The rate of growth is strong relative to the trend shown over the past year, and is accelerating. Credit worthinessCredit default swapCDS data is not available for this security.Please send all inquiries related to the report to email@example.com.Charts and report PDFs will only be available for 30 days after publishing.This document has been produced for information purposes only and is not to be relied upon or as construed as investment advice. To the fullest extent permitted by law, IHS Markit disclaims any responsibility or liability, whether in contract, tort (including, without limitation, negligence), equity or otherwise, for any loss or damage arising from any reliance on or the use of this material in any way. Please view the full legal disclaimer and methodology information on pages 2-3 of the full report.
Also on Market Tamer…
Follow Us on Facebook